Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

Ruchi Mathur, Olga Levin, Ricardo Azziz

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine/ metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number2
StatePublished - May 27 2008

Fingerprint

Contraceptives, Oral, Combined
Ethinyl Estradiol
Polycystic Ovary Syndrome
contraceptive
Progestins
Oligomenorrhea
Hyperandrogenism
Menstruation
Amenorrhea
Acne Vulgaris
Hair
Weight Gain
Therapeutics
drospirenone
Growth
Population

Keywords

  • Drospirenone
  • Oral contraceptives
  • PCOS
  • Polycystic ovary syndrome
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. / Mathur, Ruchi; Levin, Olga; Azziz, Ricardo.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 2, 27.05.2008, p. 487-492.

Research output: Contribution to journalReview article

@article{38c2106e2b6e405fa6ac94b045d6e17c,
title = "Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome",
abstract = "Polycystic ovary syndrome (PCOS) is one of the most common endocrine/ metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.",
keywords = "Drospirenone, Oral contraceptives, PCOS, Polycystic ovary syndrome, Treatment",
author = "Ruchi Mathur and Olga Levin and Ricardo Azziz",
year = "2008",
month = "5",
day = "27",
language = "English (US)",
volume = "4",
pages = "487--492",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

AU - Mathur, Ruchi

AU - Levin, Olga

AU - Azziz, Ricardo

PY - 2008/5/27

Y1 - 2008/5/27

N2 - Polycystic ovary syndrome (PCOS) is one of the most common endocrine/ metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.

AB - Polycystic ovary syndrome (PCOS) is one of the most common endocrine/ metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.

KW - Drospirenone

KW - Oral contraceptives

KW - PCOS

KW - Polycystic ovary syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=44049106156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44049106156&partnerID=8YFLogxK

M3 - Review article

C2 - 18728832

AN - SCOPUS:44049106156

VL - 4

SP - 487

EP - 492

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 2

ER -